The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

In TODAY.com's Never Have I Ever series, an expert describes what can happen when these muscles don't get enough attention.

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

SAN FRANCISCO -- Adding hormone therapy to postoperative radiotherapy did not improve overall survival (OS) for most men with prostate cancer, according to a meta-analysis of individual patient data.

Increasing use of blood tests to detect prostate cancer is leading to overworked doctors. NTNU has now created an AI diagnostic tool that can help lighten the burden.

This week, cancer researchers in New York are one step closer to answering a question that has plagued medical and environmental advocates for decades: What is the role of plastic exposure in the ...

Overall, serious adverse events occurred in 3.9% of patients over the 6-month study period. Use of relugolix among patients with prostate cancer is associated with stable quality of life (QoL), high ...

If a prostate cancer cell were a car, the androgen receptor (AR) would be part of its ignition system, enabling cancer cells to respond to hormonal signals that drive growth. For decades, therapies ...

In this observational study, researchers aimed to assess real-world use of relugolix among prostate cancer patients. Clinical Advisor, a trusted source of medical news and feature content for ...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO ...